Heat Shock Protein Antibody Titers Are Reduced by Statin Therapy in Dyslipidemic Subjects: A Pilot Study

Abstract

Antibody titers to heat shock protein (Hsp)-60 and -65 are positively related to risk of vascular disease and cardiovascular endpoints. There are few data on the factors that regulate the levels of these antibodies. It is known that the statins have antiinflammatory and immunoregulatory properties. The authors examined the effects of 2 statins, simvastatin (Zocor^®) and atorvastatin (Lipitor^®) on antibody titers to Hsp-60, -65, and -70 in a group of dyslipidemic patients. Twenty patients attending a lipid clinic, and previously not receiving lipid-lowering treatment, were treated with 10 mg of simvastatin (n=11) or atorvastatin (n=9) for 4 months. An additional 14 patients were recruited from the same clinic at the same hospital as a control group. The medication of these latter patients was unaltered for 4 months and the same parameters were measured as for the statin group. Antibody titers to Hsp-60, -65, and -70 were measured by enzyme-linked immunosorbent assay and lipoprotein profile and highly sensitive serum C-reactive protein (CRP) were measured by routine methods before and after treatment. Pretreatment and posttreatment data were compared by paired t or Mann-Whitney tests. Overall statin treatment was associated with a significant reduction in median antibody titers to Hsp-60 (17.2%, p=0.03), Hsp-65 (15.9%, p=0.003) and Hsp-70 (8.3%, p=0.006), but not in control patients. Both statins caused a reduction in median serum CRP concentrations (45% overall, p<0.05), but significant changes were not observed in the control patients. The effects on Hsp antibody titers were not related to changes in serum CRP concentrations (p>0.05). However, there was a significant correlation between changes in antibody titers to Hsp-60 vs Hsp-65 (p<0.01), Hsp-60 vs Hsp-70 (p<0.05), and Hsp-65 vs Hsp-70 (p<0.001). Statin treatment was associated with a reduction in antibody titers to Hsp-60, -65, and -70. This reduction is not fully explained by the antiinflammatory effects of the statins but may be due to their other immunomodulatory properties.

Get full access to this article

View all access options for this article.

References

Lamb DJ , El Sankary W , Ferns GAA : Molecular mimicry in atherosclerosis: A role for heat shock proteins in immunisation. Atherosclerosis 167:177-185, 2003.

Mayr M , Metzler B , Kiechl S , et al : Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coliand Chlamydia pneumoniae. Immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. Circulation 99:1560-1566, 1999.

Wick G : Atherosclerosis—an autoimmune disease due to an immune reaction against heat-shock protein 60. Herz 25:87-90, 2000.

Pockley AG , Georgiades A , Thulin T , et al : Serum heat shock protein 70 levels predict the development of atherosclerosis in subjects with established hypertension. Hypertension 42:235-238, 2003.

Prummel MF , VanPareren Y , Bakker O , et al : Anti-heat shock protein (hsp)72 antibodies are present in patients with Graves’ disease (GD) and in smoking control subjects. Clin Exp Immunol 110:292-295, 1997.

Xu QB , Kiechl S , Mayr M , et al : Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Clinical significance determined in a follow-up study. Circulation 100:1169-1174, 1999.

Hoppichler F , Koch T , Dzien A , et al : Prognostic value of antibody titre to heat-shock protein 65 on cardiovascular events. Cardiology 94:220-223, 2000.

Zhu JH , Quyyumi AA , Rott D , et al : Antibodies to human heat-shock protein 60 are associated with the presence and severity of coronary artery disease. Evidence for an autoimmune component of atherogenesis. Circulation 103:1071-1075, 2001.

Kanwar RK , Kanwar JR , Wang DM , et al : Temporal expression of heat shock proteins 60 and 70 at lesion-prone sites during atherogenesis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 21:1991-1997, 2001.

10.

George J , Shoenfeld Y , Afek A , et al : Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein-65. Arterioscler Thromb Vasc Biol 19:505-510, 1999.

11.

Afek A , George J , Gilburd B , et al : Immunization of low-density lipoprotein receptor-deficient (LDL-RD) mice with heat shock protein 65 (HSP-65) promotes early atherosclerosis. J Autoimmun 14:115-121, 2000.

12.

George J , Greenberg S , Barshack I , et al : Accelerated intimal thickening in carotid arteries of balloon-injured rats after immunization against heat shock protein 70. J Am Coll Cardiol 38:1564-1569, 2001.

13.

Pedersen TR , Kjekshus J , Berg K , et al : Randomized trial of cholesterol-lowering in 4,444 patients with coronary-heart-disease—the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389, 1994.

14.

Shepherd J , Cobbe SM , Ford I , et al : Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301-1307, 1995.

15.

Collins R , Armitage J , Parish S , et al : MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: A randomised placebo-controlled trial. Lancet 361:2005-2016, 2003.

16.

[Anon] : Pleiotropic effects of statins may benefit cardiovascular system. Can J Cardiol 14:777, 1998.

17.

Davignon J , Laaksonen R : Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol 10:543-559, 1999.

18.

Sukhova GK , Williams JK , Libby P : Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol 22:1452-1458, 2002.

19.

Shimizu K , Aikawa M , Takayama K , et al : Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins. Circulation 108:2113-2120, 2003.

20.

Ferns GAA : Differential effects of statins on serum CRP levels: Implications of recent clinical trials. Atherosclerosis 169:349-351, 2003.

21.

Rikitake Y , Kawashima S , Takeshita S , et al : Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 154:87-96, 2001.

22.

Wassmann S , Laufs U , Muller K , et al : Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 22:300-305, 2002.

23.

Raggatt LJ , Partridge NC : HMG-CoA reductase inhibitors as immunomodulators. Potential use in transplant rejection. Drugs 62:2185-2191, 2002.

24.

Weitz-Schmidt G : Lymphocyte function-associated antigen-1 blockade by statins: Molecular basis and biological relevance. Endothelium 10:43-47, 2003.

25.

Friedewald WT , Levy RJ , Fredrickson DS : Estimation of low-density lipoprotein cholesterol in plasma without the use of preparative ultracentrifugation. Clin Chim Acta 18:499-502, 1972.

26.

Xu Q , Willeit J , Marosi M , et al : Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet 341:255-259, 1993.

27.

Ghayour-Mobarhan M , Lamb DJ , Ferns GAA , et al : Antibody titres to heat shock protein 60, 65, and 70 are elevated in dyslipidaemic patients with established CHD (abstract). Atherosclerosis 5:120, 2004.

28.

Jialal I , Stein D , Balis D , et al : Effects of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high-sensitivity C-reactive protein levels. Circulation 103:1933-1935, 2001.

29.

Mulhaupt F , Matter CM , Kwak BR , et al : Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res 59:755-766, 2003.

30.

Wang TD , Chen WJ , Lin JW , et al : Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: Relations with baseline lipid profiles. Atherosclerosis 170:315-323, 2003.

31.

Mulhaupt F , Matter CM , Kwak BR , et al : Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res 59:755-766, 2003.

32.

Homma Y , Homma K , Iizuka S , et al : Effects of fluvastatin on plasma levels of low-density lipoprotein subfractions, oxidized low-density lipoprotein, and soluble adhesion molecules: A twenty-four-week, open-label, dose-increasing study. Curr Ther Res Clin Exp 64:236-247, 2003.

33.

Wang X , Tokuda H , Hatakeyama D , et al : Mechanism of simvastatin on induction of heat shock protein in osteoblasts. Arch Biochem Biophys 415:6-13, 2003.

34.

Sims TJ , Lernmark A , Mancl LA , et al : Serum IgG to heat shock proteins and Porphyromonas gingivalis antigens in diabetic patients with periodontitis. J Clin Periodontol 29:551-562, 2002.

35.

Oranje WA , Sels JP , Rondas-Colbers GJ , et al : Effect of atorvastatin on LDL oxidation and antioxidants in normocholesterolemic type 2 diabetic patients. Clin Chim Acta 311:91-94, 2001.

36.

Nissen SE , Tuzcu EM , Schoenhagen P , et al : Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 291:1071-1080, 2004.

37.

Cannon CP , Braunwald E , McCabe CH , et al : Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495-1504, 2004.

38.

Kent SM , Flaherty PJ , Coyle LC , et al : Effect of atorvastatin and pravastatin on serum C-reactive protein. Am Heart J 145:e8, 2003.

39.

Albert MA , Danielson E , Rifai N , et al : Effect of statin therapy on C-reactive protein levels. The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study. JAMA 286:64-70, 2001.

40.

Wan MX , Schramm R , Klintman D , et al : A statin-based inhibitor of lymphocyte function antigen-1 protects against ischemia/reperfusion-induced leukocyte adhesion in the colon. Br J Pharmacol 140:395-401, 2003.

41.

Schett G , Xu QB , Amberger A , et al : Autoantibodies against heat shock protein 60 mediate endothelial cytotoxicity. J Clin Invest 96:2569-2577, 1995.